We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-6.38%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$952M
AUM Growth
+$36.2M
Cap. Flow
+$167M
Cap. Flow %
17.57%
Top 10 Hldgs %
50.62%
Holding
63
New
7
Increased
16
Reduced
13
Closed
4

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$67.2M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$61M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$50M
4
CBIO
Crescent Biopharma
CBIO
+$47.3M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$21M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$55.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20.5M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$19.5M
4
CYTK icon
Cytokinetics
CYTK
+$12.7M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$82.7M 8.69%
4,639,413
– –
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$61.7M 6.48%
+2,844,145
New +$67.2M
IONS icon
3
Ionis Pharmaceuticals
IONS
$8.85B
$56M 5.89%
+935,548
New +$61M
ACIU icon
4
AC Immune
ACIU
$241M
$55.9M 5.88%
11,297,911
+1,478,477
+15% +$7.92M
CYTK icon
5
Cytokinetics
CYTK
$10.9B
$47.4M 4.98%
4,165,558
-1,011,320
-20% -$12.7M
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$46.6M 4.89%
+305,076
New +$50M
XOMA
7
DELISTED
Xoma
XOMA
$35.1M 3.69%
1,796,942
– –
RCUS icon
8
Arcus Biosciences
RCUS
$3.55B
$32.6M 3.42%
3,579,023
+43,800
+1% +$352K
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$32.1M 3.38%
437,565
– –
CBIO
10
Crescent Biopharma
CBIO
$555M
$31.7M 3.33%
+73,618
New +$47.3M
KURA icon
11
Kura Oncology
KURA
$826M
$30.3M 3.19%
1,998,276
-205,843
-9% -$3.66M
REPL icon
12
Replimune Group
REPL
$24.3M 2.56%
1,749,709
+25,100
+1% +$308K
DCPH
13
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$24.1M 2.53%
+710,697
New +$21M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$24.1M 2.53%
308,984
-218,269
-41% -$20.5M
MTEM
15
DELISTED
Molecular Templates, Inc.
MTEM
$22.3M 2.34%
225,374
+8,273
+4% +$772K
CALA
16
DELISTED
Calithera Biosciences, Inc
CALA
$20.9M 2.19%
337,524
– –
PVLA
17
Palvella Therapeutics
PVLA
$2.15B
$18.2M 1.92%
66,874
+17,446
+35% +$6.75M
INFI
18
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$17.9M 1.89%
17,426,968
– –
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$17.6M 1.85%
1,223,925
– –
XENE icon
20
Xenon Pharmaceuticals
XENE
$6.2B
$15.7M 1.65%
1,741,600
– –
ARQL
21
DELISTED
Arqule Inc
ARQL
$15.1M 1.59%
2,108,662
+1,335,203
+173% +$12.5M
FPRX
22
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$14.6M 1.53%
3,765,168
+761,826
+25% +$4.18M
CTMX icon
23
CytomX Therapeutics
CTMX
$714M
$13.9M 1.46%
1,877,148
+3,531
+0.2% +$34.8K
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.73B
$13.2M 1.39%
1,764,784
– –
IDYA icon
25
IDEAYA Biosciences
IDYA
$3.5B
$13M 1.36%
1,441,429
-64,000
-4% -$488K
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2019 Portfolio in Review

As of Q3 2019, BVF Inc held 63 positions worth $952M, up 4% from $916M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

BVF Inc deployed $167M of net new capital in Q3 2019, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was SpringWorks Therapeutics: 2,844,145 shares worth $61.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $20.5M trimmed.

  • BVF Inc's largest Q3 2019 buy was SpringWorks Therapeutics: 2,844,145 shares worth $61.7M.
  • BVF Inc added most to Arqule Inc in Q3 2019, an estimated $12.5M increase.
  • BVF Inc's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $20.5M.
  • BVF Inc fully exited Array Biopharma Inc in Q3 2019, selling an estimated $55.3M.
  • BVF Inc's ten largest holdings make up 51% of its $952M portfolio in Q3 2019.
  • BVF Inc opened 7 new positions and closed 4 in Q3 2019.
  • BVF Inc's portfolio value rose 4% quarter-over-quarter to $952M.

Based on BVF Inc's 13F filing for Q3 2019, filed 14 Nov 2019.